ArticleBMC gastroenterology2026
The effect of the use of proton pump inhibitors (PPI) on complications in patients with cirrhosis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimIn our study, we aimed to investigate the effect of PPI use on peritonitis, and hepatic encephalopathy in patients with liver cirrhosis. MATERIALS AND
methodsOur study was conducted on 220 patients. Patients with cirrhosis were divided into two groups PPI users and non-users. After the patients who did not use PPIs in their records were informed that they should not use PPIs in the future, both groups were followed up for three more years. 129 (58.6%) of the patients were PPI users and 91 (41.4%) of the patients were not PPI users. At the end of three years, these two groups were compared in terms of peritonitis. and encephalopathy.
resultsThe presence of encephalopathy was compared with PPI use status. Encephalopathy was present in 20 (16.2%) of PPI users, while 12 (13.2%) of non-PPI users had encephalopathy. No significant difference was found between the groups (p=0.230). When the presence of peritonitis in the patients was analyzed, peritonitis was found in 30 (23.7%) of the patients using PPIs, while 16 (17.6%) of the patients not using PPIs had peritonitis. There was no statistically significant difference between the groups (p=0.103).
conclusionIn our study, there was no statistically significant association between PPI use, peritonitis, and encephalopathy in patients with cirrhosis. It may be possible that this association may emerge in patients with decompensated cirrhosis and longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.